Telemedicine to Reduce Disparities in the Identification and Treatment of Neonatal Encephalopathy
NCT ID: NCT05155111
Last Updated: 2024-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
23 participants
INTERVENTIONAL
2021-12-22
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Telemedicine to Improve Use of Therapeutic Hypothermia in Rural Settings
NCT03706417
Assessment of Tele-expertise for the Interpretation of MRI Among Neonates With High Risk of Neurological Sequelae
NCT03706651
CoolCap Followup Study-Coordination of Participating Centers
NCT00581581
Early Neurological Outcome in Newborns With Mild Encephalopathy:a Regional Network
NCT05785481
Detection and Quantification of Neonatal Intraventricular Hemorrhage
NCT01899651
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In Maine, the investigators have successfully implemented telemedicine both in the tertiary care center and in the rural community hospital to permit visual evaluation of neonates and inform joint decision making in these challenging instances. Telemedicine provides the opportunity to have synchronous, unscheduled immediate expert consultation for neonatologists with pediatric neurology in the tertiary care center and for primary care physicians with both specialists in the community hospital setting. The objective of the present study is to develop the telemedicine consultative network to continue to improve patient selection for TH. The investigators aim to use telemedicine consults in three tertiary care centers (Maine Medical Center, Northern Light Eastern Maine Medical Center and the University of Vermont Medical Center) to develop evidence for the threshold at which neonates can be safely excluded from TH treatment. In Aim 1, the investigators will assess neonates with milder symptoms at least twice in the first 6 hours of life and for those not meeting criteria for moderate or severe neonatal encephalopathy, perform electroencephalogram (EEG) to rule out seizures and MRI of the brain to rule out injury. In aim 2, the investigators will compare the interrater reliability between the neonatologist neonatal encephalopathy exam and the one performed via telemedicine by the pediatric neurologist.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Telemedicine arm
Neonates will have telemedicine consultation to evaluate symptoms of neonatal encephalopathy
Telemedicine consult
A joint assessment between Neonatologist at bedside and Neurologist by telemedicine will be performed to assess severity of neonatal encephalopathy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Telemedicine consult
A joint assessment between Neonatologist at bedside and Neurologist by telemedicine will be performed to assess severity of neonatal encephalopathy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Umbilical cord pH 7.01 to 7.15 or base deficit between -10 and -16 AND one of the following;
* a perinatal event, defined as severe fetal heart rate abnormality such as category 2 or 3 tracing with recurrent variable decelerations, prolonged decelerations or recurrent late decelerations, umbilical cord prolapse/rupture, uterine rupture, significant placental abruption, maternal trauma or hemorrhage or cardiopulmonary arrest)
* 10-minute Apgar score \< 5
* Need for respiratory support for \>10 minutes not otherwise due to a primary pulmonary process
Exclusion Criteria
* Gestational age less than or equal to 35 6/7 weeks
* Birthweight \<1800 grams
* Non-English speaking parents due to time constraints to perform the consent process
0 Hours
6 Hours
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MaineHealth
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alexa Craig
Attending Neonatal and Pediatric Neurologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexa K Craig, MD
Role: PRINCIPAL_INVESTIGATOR
physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maine Medical Center
Portland, Maine, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1781443
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.